NEWARK, Del, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The global parkinson’s disease therapeutic market is on a steady growth trajectory, with a projected market size of USD 4.3 billion in 2024. As advancements in medical research and technology continue to drive innovation, the market is expected to reach an estimated USD 6.7 billion by 2034, reflecting a compound annual growth rate (CAGR) of 5.1% over the next decade.
Key drivers of this market growth include significant advancements in medical research, such as gene therapy, stem cell research, and novel drug delivery systems. These innovations are offering new hope for patients by providing more effective treatment options. As a result, patients can look forward to enhanced therapeutic outcomes and improved quality of life.
The rise in awareness and early diagnosis of Parkinson’s disease is also playing a crucial role in market expansion. The adoption of advanced diagnostic techniques, including cutting-edge imaging technologies and biomarkers, is enabling earlier intervention, which significantly enhances the effectiveness of treatments and improves patient outcomes.
Furthermore, increased investment in research and development by pharmaceutical companies and governmental bodies is fostering a climate of innovation. Partnerships between biotech firms and research institutions are accelerating the discovery of new drugs and therapies, providing patients with more treatment options. The approval of these new drugs and therapies by regulatory bodies, such as the FDA, is further fueling market growth.
The adoption of digital health technologies, including wearable devices and telemedicine, is also making a significant impact on the management of Parkinson’s disease. These technologies are improving patient adherence to treatment regimens and allowing for more effective disease management, contributing to the overall growth of the market.
As the Parkinson’s disease therapeutic market continues to evolve, stakeholders across the healthcare spectrum remain committed to advancing research, improving patient outcomes, and meeting the growing demand for effective treatments.
Key Takeaways: Parkinson's disease Therapeutic Market
- The Parkinson's disease therapeutic market is experiencing steady growth, driven by increasing prevalence and advancements in treatment options.
- The global market is projected to reach USD 6.7 billion by 2034, with a CAGR of 5.1%.
- The United States is the dominant market, both in terms of market share and growth rate.
- The growing number of older adults, who are at a higher risk of Parkinson's disease, is a significant driver of market expansion.
- Enhanced public awareness and improved diagnostic techniques are leading to earlier detection and treatment.
- The development of innovative therapies and treatment options is contributing to market growth.
- United States The market is characterized by high prevalence, robust healthcare infrastructure, and significant research and development efforts.
- China The market is expanding due to a growing generic manufacturing sector, increased product penetration, and rising disease prevalence.
- United Kingdom Government support, strong healthcare system, and pharmaceutical sector advancements are driving market growth.
- The Parkinson's disease therapeutic market is poised for continued growth due to various factors.
- The United States, China, and the United Kingdom are key markets with significant potential.
- Advancements in treatment options and increased awareness are essential for improving patient outcomes and driving market expansion.
“The Parkinson's disease therapeutic market is witnessing significant growth driven by increasing prevalence, advancements in drug development, and rising demand for innovative treatments. Ongoing research and novel therapies, including gene therapy and stem cell treatments, are expected to further expand market opportunities in the coming years”, opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).
Competitive Landscape:
The Parkinson’s disease therapeutic market is marked by intense competition among leading pharmaceutical giants, biotech companies, and innovative startups.
Industry leaders like Pfizer, AbbVie, and GlaxoSmithKline are making substantial investments in R&D to advance treatment options. At the same time, emerging startups are gaining traction with breakthrough technologies such as gene therapy and neurostimulation devices.
Companies are frequently engaging in strategic partnerships, mergers, and acquisitions to broaden their portfolios and enhance market presence. The drive to develop disease-modifying therapies and personalized medicine solutions further heightens competition, fueling ongoing innovation and market growth.
The Latest Reports from Get Old Source Are Here: https://www.einpresswire.com/article/666814335/parkinson-s-disease-market-poised-to-flourish-estimated-at-us-17-12-billion-by-2033-with-12-2-cagr-fmi-study
Parkinson’s disease Therapeutic Market by Category
By Drug Class:
By drug class, the industry is divided into carbidopa-levodopa, dopamine agonists, mao-b inhibitors, COMT inhibitors, anticholinergics and others.
By Distribution Channel:
By distribution channel, the industry is divided into hospital pharmacy, retail pharmacy and online pharmacy.
By Brand:
By brand, the industry is divided into branded and generics.
By Route of Administration:
By route of administration, the industry is divided into oral, injectable, intestinal infusion, subcutaneous and others.
By Region:
As per region, the industry is divided into North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe and Middle East & Africa.
Spanish Translation:
El mercado terapéutico mundial de la enfermedad de Parkinson se encuentra en una trayectoria de crecimiento constante, con un tamaño de mercado proyectado de USD 4.3 mil millones en 2024. A medida que los avances en la investigación médica y la tecnología continúan impulsando la innovación, se espera que el mercado alcance un estimado de USD 6.7 mil millones para 2034, lo que refleja una tasa de crecimiento anual compuesta (CAGR) del 5,1% durante la próxima década.
Los impulsores clave de este crecimiento del mercado incluyen avances significativos en la investigación médica, como la terapia génica, la investigación con células madre y los nuevos sistemas de administración de medicamentos. Estas innovaciones ofrecen nuevas esperanzas para los pacientes al proporcionar opciones de tratamiento más efectivas. Como resultado, los pacientes pueden esperar mejores resultados terapéuticos y una mejor calidad de vida.
El aumento de la conciencia y el diagnóstico temprano de la enfermedad de Parkinson también está desempeñando un papel crucial en la expansión del mercado. La adopción de técnicas de diagnóstico avanzadas, incluidas tecnologías de imágenes y biomarcadores de vanguardia, está permitiendo una intervención más temprana, lo que mejora significativamente la efectividad de los tratamientos y mejora los resultados del paciente. Además, el aumento de la inversión en investigación y desarrollo por parte de las empresas farmacéuticas y los organismos gubernamentales está fomentando un clima de innovación. Las asociaciones entre empresas de biotecnología e instituciones de investigación están acelerando el descubrimiento de nuevos fármacos y terapias, lo que ofrece a los pacientes más opciones de tratamiento. La aprobación de estos nuevos fármacos y terapias por parte de organismos reguladores, como la FDA, está impulsando aún más el crecimiento del mercado.
La adopción de tecnologías de salud digital, incluidos los dispositivos portátiles y la telemedicina, también está teniendo un impacto significativo en el tratamiento de la enfermedad de Parkinson. Estas tecnologías están mejorando la adherencia de los pacientes a los regímenes de tratamiento y permitiendo un manejo más eficaz de la enfermedad, lo que contribuye al crecimiento general del mercado.
A medida que el mercado terapéutico de la enfermedad de Parkinson continúa evolucionando, las partes interesadas en todo el espectro de la atención médica siguen comprometidas con el avance de la investigación, la mejora de los resultados de los pacientes y la satisfacción de la creciente demanda de tratamientos efectivos.
Puntos clave: mercado terapéutico de la enfermedad de Parkinson
• El mercado terapéutico de la enfermedad de Parkinson está experimentando un crecimiento constante, impulsado por la creciente prevalencia y los avances en las opciones de tratamiento.
• Se proyecta que el mercado global alcance los USD 6.7 mil millones para 2034, con una CAGR del 5,1%.
• Estados Unidos es el mercado dominante, tanto en términos de participación de mercado como de tasa de crecimiento.
• El creciente número de adultos mayores, que tienen un mayor riesgo de padecer la enfermedad de Parkinson, es un impulsor significativo de la expansión del mercado.
• Una mayor conciencia pública y técnicas de diagnóstico mejoradas están llevando a una detección y un tratamiento más tempranos.
• El desarrollo de terapias y opciones de tratamiento innovadoras está contribuyendo al crecimiento del mercado.
• Estados Unidos El mercado se caracteriza por una alta prevalencia, una infraestructura de atención médica sólida y esfuerzos significativos de investigación y desarrollo.
• China El mercado se está expandiendo debido a un creciente sector de fabricación de genéricos, una mayor penetración de productos y una creciente prevalencia de la enfermedad.
• El apoyo del gobierno del Reino Unido, el sólido sistema de atención médica y los avances del sector farmacéutico están impulsando el crecimiento del mercado.
• El mercado terapéutico de la enfermedad de Parkinson está preparado para un crecimiento continuo debido a varios factores.
• Estados Unidos, China y el Reino Unido son mercados clave con un potencial significativo.
• Los avances en las opciones de tratamiento y una mayor concienciación son esenciales para mejorar los resultados de los pacientes e impulsar la expansión del mercado.
Panorama competitivo:
El mercado terapéutico de la enfermedad de Parkinson está marcado por una intensa competencia entre los principales gigantes farmacéuticos, empresas de biotecnología y nuevas empresas innovadoras.
Los líderes de la industria como Pfizer, AbbVie y GlaxoSmithKline están realizando inversiones sustanciales en I+D para avanzar en las opciones de tratamiento. Al mismo tiempo, las empresas emergentes están ganando terreno con tecnologías innovadoras como la terapia genética y los dispositivos de neuroestimulación.
Las empresas participan con frecuencia en asociaciones estratégicas, fusiones y adquisiciones para ampliar sus carteras y mejorar su presencia en el mercado. El impulso por desarrollar terapias que modifiquen las enfermedades y soluciones de medicina personalizada aumenta aún más la competencia, lo que impulsa la innovación continua y el crecimiento del mercado.
Mercado terapéutico de la enfermedad de Parkinson por categoría
Por clase de fármaco:
Por clase de fármaco, la industria se divide en carbidopa-levodopa, agonistas de la dopamina, inhibidores de la MAO-B, inhibidores de la COMT, anticolinérgicos y otros.
Por canal de distribución:
Por canal de distribución, la industria se divide en farmacia hospitalaria, farmacia minorista y farmacia en línea.
Por marca:
Por marca, la industria se divide en medicamentos de marca y genéricos.
Por vía de administración:
Por vía de administración, la industria se divide en oral, inyectable, infusión intestinal, subcutánea y otros.
Por región:
Según la región, la industria se divide en América del Norte, América Latina, Europa occidental, Asia meridional, Asia oriental, Europa oriental y Oriente Medio y África.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain:
The infectious disease diagnostics market size is expected to grow at a steady pace, reaching USD 21.5 billion in 2024. It is estimated that this positive trend will continue, with the market reaching USD 43.2 billion by 2034.
The global neurodegenerative disease market share from an estimated valuation of USD 52 billion in 2024 to a forecasted USD 102.4 billion by 2034 at a CAGR of 7%, heralds a significant shift in the healthcare landscape.
The global autoimmune disease therapeutics market demand is likely to be valued at USD 71,466.47 million in 2023 and is predicted to secure a moderate-paced CAGR of 5.6% during the forecast period. The market is expected to grow at a value of USD 123,507.30 million by 2033. A historical CAGR of 3.6% has been recorded during the analysis by Future Market Insights.
The rare disease clinical trials market outlook is projected to be valued at USD 12,566.14 million in 2023 and is expected to rise to USD 31,715.25 million by 2033. The sales of rare disease clinical trials are expected to record a significant CAGR of 9.7% during the forecast period.
The global intravenous pegloticase market trends with a slowly progressing CAGR of 13.8% from 2023 to 2033, this market is expected to garner USD 3.19 Billion by 2023 and USD 11.61 Billion by 2033.
The projected global photoacoustic microscopy market opportunity is likely to hit the USD 120 billion valuation mark by 2024. Owing to an impressive CAGR of 17.3% through 2034, the ecosystem is set to reach USD 591.6 million by the end of the forecast period.
The global intravenous iron drugs market forecast is projected to reach USD 2.8 Billion in 2022 and is expected to growth USD 6.3 Billion by 2032 at a CAGR of 8.5%.
The global venous stents market strategies valued at approximately USD 990.5 million in 2023, is expected to soar to an impressive USD 2.2 billion by the end of 2033. This growth represents a substantial compound annual growth rate (CAGR) of 8.4% from 2023 to 2033.
The global intravenous pegloticase market trends with a slowly progressing CAGR of 13.8% from 2023 to 2033, this market is expected to garner USD 3.19 Billion by 2023 and USD 11.61 Billion by 2033.
The global photoacoustic microscopy market overview is likely to hit the USD 120 billion valuation mark by 2024. Owing to an impressive CAGR of 17.3% through 2034, the ecosystem is set to reach USD 591.6 million by the end of the forecast period.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact FMI:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
